TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26216931

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Prasugrel (early)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Prasugrel (late)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ticagrelor (early)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ticagrelor (late)
Number of subjects: 124
Study: 24305430

Group type: EXPERIMENTAL
Intervention: Test foaming liquid facial cleanser containing HMPs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Commercial gentle liquid nonfoaming facial cleanser
Number of subjects: 40
Study: 21532082

Group type: EXPERIMENTAL
Intervention: Peer mentor plus usual care
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74
Study: 18054000

Group type: EXPERIMENTAL
Intervention: SIVF catheter
Number of subjects: 400

Group type: COMPARATOR
Intervention: EW catheter
Number of subjects: 400
Study: 16941701

Group type: EXPERIMENTAL
Intervention: PEG-interferon alpha-2b (PEG-IFN) and lamivudine
Number of subjects: 266

Group type: COMPARATOR
Intervention: PEG-interferon alpha-2b (PEG-IFN) monotherapy
Number of subjects: 266
Study: 12953339

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 128
Study: 10743815

Group type: EXPERIMENTAL
Intervention: Bilateral SI joint injections of triamcinolone hexacetonide (40 mg/joint) under computer tomographic guidance
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as patients without treatment)
Number of subjects: 19
Study: 8614505

Group type: EXPERIMENTAL
Intervention: d-cycloserine (15 mg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 1390591

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (40 mg/day) + n-3 polyunsaturated fatty acids (5.3 g eicosapentaenoic and docosahexaenoic acids)
Number of subjects: 6

Group type: COMPARATOR
Intervention: n-6 polyunsaturated fatty acids (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (5.3 g)
Number of subjects: 6
Study: 2861223

Group type: EXPERIMENTAL
Intervention: Hexamethonium bromide plus placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hexamethonium bromide alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hexamethonium bromide plus atropine sulphate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 6
Study: 28861602

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 56
Study: 29469944

Group type: EXPERIMENTAL
Intervention: Chewing gum three times a day for 30 minutes
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2000
Study: 26851700

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25178312

Group type: EXPERIMENTAL
Intervention: Geriatric screening and intervention
Number of subjects: 780

Group type: COMPARATOR
Intervention: Standard ED care
Number of subjects: 780
Study: 22316799

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention including biofeedback
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention without biofeedback
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group without intervention
Number of subjects: 66
Study: 21130326

Group type: EXPERIMENTAL
Intervention: Pro-seal (light-cured filled resin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Vanish)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aegis-Ortho (ACP cement)
Number of subjects: 100

Group type: COMPARATOR
Intervention: MI Paste (casein phosphopeptide-ACP paste)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (Transbond XT resin)
Number of subjects: 100
Study: 17595895

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin test formulation (Novell Pharmaceutical Laboratories, Indonesia)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ciprofloxacin reference formulation (Quimica Farmaceutica Bayer, Spain)
Number of subjects: 24
Study: 15771028

Group type: EXPERIMENTAL
Intervention: Nasojejunal tube (NJT) placement
Number of subjects: 237

Group type: COMPARATOR
Intervention: No nasojejunal tube (no-NJT) placement
Number of subjects: 237
Study: 12495602

Group type: EXPERIMENTAL
Intervention: Cefepime 1 to 2 g IV twice daily or three times a day for 3 to 21 days
Number of subjects: 317

Group type: COMPARATOR
Intervention: Broad-spectrum combination therapy (IV ampicillin, cephalothin, or ceftriaxone +/- aminoglycoside) for 3 to 21 days
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 317

Group type: COMPARATOR
Intervention: Broad-spectrum combination therapy
Number of subjects: 317
Study: 9577999

Group type: EXPERIMENTAL
Intervention: High dose gabapentin monotherapy (3,000‐4,800 mg/day)
Number of subjects: 45
Study: 9327485

Group type: EXPERIMENTAL
Intervention: Monthly newsletter
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Self-help behavior change kit
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Demographic correlates
Number of subjects: 345
Study: 2021990

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 40 mg iv pretreatment with cimetidine 200 mg iv
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 200 mg iv without diphenhydramine pretreatment
Number of subjects: 0
Study: 7214686

Group type: EXPERIMENTAL
Intervention: Oxatomide (30 mg/capsule, 2-4 capsules daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Chlorpheniramine (5 mg/capsule, 2-4 capsules daily)
Number of subjects: 41
Study: 30741797

Group type: EXPERIMENTAL
Intervention: Relugolix (40 mg, oral, once daily)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Leuprorelin (1.88 mg or 3.75 mg, monthly injection)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 288

Group type: COMPARATOR
Intervention: Leuprorelin
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Relugolix and Leuprorelin
Number of subjects: 288
Study: 27749616

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided steroid injection (40 mg of methylprednisolone)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Landmark-guided steroid injection (40 mg of methylprednisolone)
Number of subjects: 47
Study: 23653426

Group type: EXPERIMENTAL
Intervention: 5-mg donepezil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 7.5-mg donepezil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21854068

Group type: EXPERIMENTAL
Intervention: Pea protein hydrolysate (PPH) administered orally at doses of 100 and 200 mg/kg body weight to SHR; 3-week randomized double-blind placebo-controlled trial in humans.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Unhydrolyzed pea protein isolate (PPI) administered orally to SHR.
Number of subjects: 7
Study: 19955890

Group type: EXPERIMENTAL
Intervention: AWS (PENTAX-AWS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 40
Study: 17586102

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin 10‐20mg/day
Number of subjects: 8214

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 8214
Study: 15792017

Group type: EXPERIMENTAL
Intervention: VIBOVITmama supplementation (15 mg of zinc, 2 mg of copper, 20 microg of selenium)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: VIBOVITmama supplementation
Number of subjects: 138
Study: 11728483

Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol orally
Number of subjects: 499

Group type: COMPARATOR
Intervention: 10 IU oxytocin intramuscularly
Number of subjects: 499
Study: 9008373

Group type: EXPERIMENTAL
Intervention: Self-selection based on gender-linked differences in support for group inequality (social dominance orientation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hiring biases based on matching job applicants' group equality values with the hierarchy function of the job
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender-stereotyped hiring biases
Number of subjects: 0
Study: 8331198

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 0
Study: 3013265

Group type: EXPERIMENTAL
Intervention: Enalapril 20-40 mg plus hydrochlorothiazide 25-100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol 50-100 mg plus hydrochlorothiazide 25-100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril plus hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol plus hydrochlorothiazide
Number of subjects: 0
Study: 29254067

Group type: EXPERIMENTAL
Intervention: Worry induction
Number of subjects: 171

Group type: COMPARATOR
Intervention: Relaxation induction
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Worry induction in GAD
Number of subjects: 171

Group type: COMPARATOR
Intervention: Relaxation induction in GAD
Number of subjects: 171

Group type: COMPARATOR
Intervention: Worry induction in Controls
Number of subjects: 171

Group type: COMPARATOR
Intervention: Relaxation induction in Controls
Number of subjects: 171
Study: 27199056

Group type: EXPERIMENTAL
Intervention: Papillary muscle approximation with undersizing restrictive mitral annuloplasty (PMA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Restrictive annuloplasty (RA)
Number of subjects: 96
Study: 24128996

Group type: EXPERIMENTAL
Intervention: LiquiBand Surgical S (LB)
Number of subjects: 433

Group type: COMPARATOR
Intervention: High Viscosity Dermabond (DB)
Number of subjects: 433
Study: 22336104

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Action Research Arm Test (ARAT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sensorimotor and kinematic measures of reach and grasp
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clinical measures of disability
Number of subjects: 51
Study: 20231319

Group type: EXPERIMENTAL
Intervention: Meta-cognitive therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 88
Study: 18435955

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stents (PES)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Bare Metal Stents (BMS)
Number of subjects: 956
Study: 15863811

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional antipsychotic medication
Number of subjects: 97
Study: 12431860

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 14
Study: 10348762

Group type: EXPERIMENTAL
Intervention: Mupirocin applied to the anterior nares for 5 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo applied to the anterior nares for 5 days
Number of subjects: 102
Study: 7782178

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate ear drops
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide ear drops
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 110
Study: 1887981

Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 60
Study: 6355186

Group type: EXPERIMENTAL
Intervention: Prednisone (15 mg/d per subject for 7 days)
Number of subjects: 10
Study: 31376437

Group type: EXPERIMENTAL
Intervention: Extreme spicy food cravers
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-cravers
Number of subjects: 51
Study: 28248154

Group type: EXPERIMENTAL
Intervention: Collaborative care (low-intensity intervention including behavioral activation delivered by a case manager for an average of six sessions over 7-8 weeks, alongside usual GP care)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 705

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 705
Study: 26619086

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 1465
Study: 24313916

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 100 mg plus MTX
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg plus MTX
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg plus MTX
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 316
Study: 22523181

Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised aerobic exercise training (AET)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study: 19670459

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 17584318

Group type: EXPERIMENTAL
Intervention: Cyclosporin administered before meals (group B)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cyclosporin administered after meals (group A)
Number of subjects: 37
Study: 15155118

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan plus Ramipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11238232

Group type: EXPERIMENTAL
Intervention: Two doses of ETEC vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First dose of ETEC vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two full vaccine doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-third of a full dose of CFA-ETEC bacteria
Number of subjects: 0
Study: 9840528

Group type: EXPERIMENTAL
Intervention: Liver embolization with gel foam powder
Number of subjects: 41
Study: 7517169

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone (control)
Number of subjects: 0
Study: 2543304

Group type: EXPERIMENTAL
Intervention: COMP (cyclophosphamide, vincristine, methotrexate, procarbazine)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: COMP-VAN (cyclophosphamide, vincristine, methotrexate, procarbazine and etoposide, adriamycin, nimustine)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CAV-PVP hybrid regimen (cyclophosphamide, adriamycin, vincristine and cisplatin, etoposide)
Number of subjects: 181

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CT plus chest RT (40 Gy)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Not receiving PCI
Number of subjects: 181
Study: 4826316

Group type: EXPERIMENTAL
Intervention: 20 kg back load
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 kg handcart
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 60 kg handcart
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 kg handcart
Number of subjects: 8
Study: 30536797

Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product of posaconazole oral suspension
Number of subjects: 0
Study: 28942444

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) measured in angina patients (n = 128)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve (CFVR) assessed in angina patients (n = 128)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Coronary flow velocity reserve (CFVR) assessed in reference population (n = 21)
Number of subjects: 194
Study: 26001337

Group type: EXPERIMENTAL
Intervention: Relamorelin (100 μg/d, given subcutaneously)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22977278

Group type: EXPERIMENTAL
Intervention: Interventionists with >10 Wingspan cases submitted for credentialing
Number of subjects: 213

Group type: COMPARATOR
Intervention: Sites enrolling <12 patients
Number of subjects: 213

Group type: COMPARATOR
Intervention: Interventionists with less Wingspan experience
Number of subjects: 213

Group type: COMPARATOR
Intervention: Low enrollment sites
Number of subjects: 213
Study: 21557836

Group type: EXPERIMENTAL
Intervention: Hyoscine N-butyl bromide (HBB)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 140
Study: 18773845

Group type: EXPERIMENTAL
Intervention: Aminobisphosphonates as preventive treatment at the time of diagnosis of bone metastatic prostate cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local treatments (external beam radiotherapy, bone surgery) and systemic treatments (androgen deprivation, chemotherapy)
Number of subjects: 0
Study: 16139812

Group type: EXPERIMENTAL
Intervention: Phobogenic stimuli (spiders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (neutral stimuli - mushrooms)
Number of subjects: 0
Study: 12709725

Group type: EXPERIMENTAL
Intervention: 25 mg subcutaneous etanercept twice weekly for 24 weeks
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 50 mg subcutaneous etanercept twice weekly for 24 weeks
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 10932442

Group type: EXPERIMENTAL
Intervention: Integrated mental health and substance use treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hospital treatment
Number of subjects: 0
Study: 8981131

Group type: EXPERIMENTAL
Intervention: dl-norgestrel (2 mg) with ethinyl oestradiol (200 micrograms)
Number of subjects: 540

Group type: COMPARATOR
Intervention: levonorgestrel (1 mg) with ethinyl oestradiol (200 micrograms)
Number of subjects: 540
Study: 1428162

Group type: EXPERIMENTAL
Intervention: Ceftriaxone for 3 days
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulphadiazine for 3 days
Number of subjects: 157

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Ceftriaxone vs Ampicillin/sulphadiazine
Number of subjects: 157
Study: 3908726

Group type: EXPERIMENTAL
Intervention: S6472 (750 mg b.i.d.)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cefaclor (CCL) (750 mg t.i.d.)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: S6472
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cefaclor (CCL)
Number of subjects: 250
Study: 30759761

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Number of subjects: 136
Study: 29720378

Group type: EXPERIMENTAL
Intervention: Acupuncture at PC5
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acupuncture at LU5
Number of subjects: 31
Study: 27455316

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (MC) supplementation (30 mL twice per day for 8 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA) supplementation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (MC) supplementation
Number of subjects: 16
Study: 25424425

Group type: EXPERIMENTAL
Intervention: Standard-of-care plus mobile phone-based SMS intervention for 6 months
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 216
Study: 21832285

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (irinotecan with either bolus or infused 5-fluorouracil)
Number of subjects: 567
Study: 19200959

Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG
Number of subjects: 305

Group type: COMPARATOR
Intervention: 0.5 mg GnRHa (buserelin) supplemented with 1,500 IU hCG
Number of subjects: 305
Study: 17587713

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of acetylcholine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: hs-CRP > or = 2 mg/L
Number of subjects: 199
Study: 15756035

Group type: EXPERIMENTAL
Intervention: 4‐HPR (fenretinide)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 12871005

Group type: EXPERIMENTAL
Intervention: Show group (LA syringe shown to child)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No-show group (LA syringe concealed from child)
Number of subjects: 25
Study: 9525542

Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation
Number of subjects: 6797
Study: 7640431

Group type: EXPERIMENTAL
Intervention: Cellulose triacetate (CTA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Polysulphon (PS)
Number of subjects: 31
Study: 2533802

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) plus diazepam (5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) plus meclophenoxate (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) plus placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 16
Study: 568172

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Soy-based formulas
Number of subjects: 25

Group type: COMPARATOR
Intervention: Milk-based formulas
Number of subjects: 25
Study: 31054159

Group type: EXPERIMENTAL
Intervention: Vitamin D (400 iU daily) drops
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo drops (coconut and palm kernel oil)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: UV light exposure (measured in a nonrandomized subset)
Number of subjects: 195
Study: 31424481

Group type: EXPERIMENTAL
Intervention: Clopidogrel-Aspirin
Number of subjects: 10051

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 10051